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This article contains epidemiological, demographic and other data
used for estimating health and economic burden of neurocysti-
cercosis (NCC)-associated active epilepsy in India [1]. Most of the
data are embedded in the R-code used for analyses so that the
reader is able to replicate the results or adapt the code to their own
data. However, data used to conduct sensitivity analyses to eval-
uate the effect of changing important input values such as pre-
valence and per capita income on health and economic impact of
NCC in India are included in tables. Results from sensitivity ana-
lyses are also presented in tables and ﬁgures. The paper also
includes three scenarios with different age weighting (k) and time
discounting (r) values used to estimate health and economic bur-
den of NCC in India. The data for the scenario without any age
weighting and time discounting are presented in “Estimation of
the health and economic burden of neurocysticercosis in India” [1].
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xperimental
factorsThe study population, demographic, epidemiologic, disease severity and data
associated with production losses.xperimental
featuresData were analysed using R-statistical program (R statistical package version
3.2.2, R Development Core Team (2015), http://www.r-project.org)ata source
locationIndiaata accessibility Data is within this articleo evaluate the effect of changing prevalence of neurocysticercosis (NCC) (0.5 , 1 , 1.5 and 2
values) on economic losses associated with human NCC-associated active epilepsy.
B.B. Singh et al. / Data in Brief 7 (2016) 571–581 573Value of the data The data and the code can be adapted to estimate health and economic impact of NCC in other
countries.
 The data demonstrate the importance of input variables such as prevalence, per capita income,
proportion of people seeking medical attention and case fatality on changing the disability
adjusted life years (DALY) for NCC in India.
 The data demonstrate the importance of input variables such as prevalence and per capita income
on economic losses occurring due to NCC in India.Fig. 2. Sensitivity analysis to evaluate the effect of changing annual per capita income (0.5 , 1 , 1.5 and 2 (times) of the
original input values) on economic losses due to human neurocysticercosis (NCC)-associated active epilepsy.
Table 1
Sensitivity analyses to evaluate the effect of changing prevalence, per capita income and proportion of people seeking medical attention on disability adjusted life years (DALY) for neuro-
cysticercosis (NCC) in India. Results for three scenarios with different age weighting (k) and time discounting (r) are presented here; results for the scenario without any age weighting and
time discounting are presented in Singh et al. [1].
Parameters Years of life lived with disability (in
thousands)
Years of life lost (in thousands) Disability adjusted life years (in thousands)
Median 95% UI Median 95% UI Median 95% UI
Scenario 2 (k¼1; r¼0)
Prevalence
Original input values 0.5 216.29 93.66–469.26 861.4 114.6–3394.5 1081.7 276.8–3677.0
Original input values 421.5 220.7–794.6 1680.9 236.3–6992.9 2106 582–7688
Original input values 1.5 626.8 309.8–1159.8 2483.6 321.7–8012.6 3123.5 799.7–8918.3
Original input values 2.0 832.4 437.7–1468.1 3315.9 475.8–12092.4 4150 1040–13210
Proportion of people seeking allopathic medical attention
20% Patients 577.0 280.0–1114.6 1682.2 239.1–6439.7 2265.6 717.4–7185.1
40% Patients 502.5 262.5–946.9 1676.6 232.9–6671.4 2189.6 671.1–7188.8
62% Patients 419.3 214.6–776.2 1675 226–5628 2104.0 512.9–6059.2
80% Patients 352.7 157.9–731.9 1671.1 203.1–6625.1 2033.0 470.1–7076.2
100% Patients 277.3 103.8–743.0 1672.0 232.1–6035.7 1959.5 450.6–6591.1
Case fatality
Original input values 0.5 422.1 229.8–851.5 933.81 60.36–4661.44 1358.5 355.5–5166.3
Original input values 420.7 214.4–830.0 1671.5 166.3–5437.2 2098.4 500.1–5889.9
Original input values 1.5 419.7 202.3–764.7 2418.5 441.9–8124.8 2844.1 745.8–8536.1
Original input values  2.0 422.8 220.3–812.7 3184.5 810.4–8987.7 3614 1243–9526
Scenario 3 (k¼0; r¼0.03)
Prevalence
Original input values 0.5 164.68 79.89–335.99 420.13 54.29–1898.06 588.3 158.6–2156.4
Original input values 320.7 175.7–574.6 824.4 115.2–3789.5 1149.1 319.5–4205.2
Original input values 1.5 475.8 265.5–843.9 1230.4 177.0–4934.5 1708.0 575.6–5687.1
Original input values 2.0 630.8 376.2–1197.3 1631.7 245.5–5795.6 2268.8 799.3–6406.6
Proportion of people seeking allopathic medical attention
20% patients 437.2 233.8–860.9 824.4 113.2–2944.1 1267.8 409.7–3382.6
40% patients 381.8 205.1–679.2 825.8 112.0–2800.3 1213.4 398.4–3235.9
62% patients 319.2 180.5–592.0 823.2 114.7–2770.6 1146.6 336.8–3294.5
80% patients 269.3 134.4–546.8 824.0 124.3–2862.2 1096.4 343.5–3101.9
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100% patients 210.51 92.18–607.88 825.2 116.6–2684.8 1042.6 275.4–2941.8
Case fatality
Original input values 0.5 320.4 158.4–559.6 457.40 29.59–2115.29 782.2 287.2–2481.6
Original input values 320.5 184.6–583.1 824.81 83.78–3206.29 1149.5 326.0–3554.6
Original input values 1.5 319.6 178.8–567.8 1185.0 196.2–3680.0 1505.8 445.5–3957.1
Original input values 2.0 320.8 172.9–664.6 1564.9 384.8–4791.1 1883.9 632.3–5144.9
Scenario 4 (k¼1; r¼0.03)
Prevalence
Original input values 0.5 203.54 88.35–430.85 448.94 51.49–1765.48 655.3 192.5–2065.8
Original input values 395.8 211.0–768.8 880.5 131.3–3470.5 1282.9 403.6–3938.6
Original input values 1.5 589.0 313.7–1025.3 1308.3 190.8–4298.8 1909.7 641.8–4878.9
Original input values  2.0 782.6 405.6–1310.6 1729.0 258.3–5974.9 2523.6 808.7–6907.9
Proportion of people seeking allopathic medical attention
20% Patients 541.0 253.3–1093.2 877.3 116.2–3310.5 1426.4 491.8–4050.6
40% Patients 472.2 241.1–839.5 885.4 125.3–3112.1 1366.6 478.5–3601.7
62% Patients 397.4 196.1–762.0 878.6 107.2–3307.2 1281.5 455.4–3656.5
80% Patients 331.5 159.6–718.4 877.5 120.4–3101.9 1216.4 335.6–3548.5
100% patients 259.65 98.31–662.27 878.0 123.7–2894.9 1146.6 299.8–3142.2
Case fatality
Original input values 0.5 397.3 211.2–760.6 489.03 27.44–2199.97 892.0 324.3–2835.4
Original input values 396.4 209.7–779.2 878.76 85.16–3249.93 1284 397–3777
Original input values 1.5 395.4 184.8–800.2 1265.6 238.2–4062.4 1668.7 550.6–4493.1
Original input values 2.0 396.8 201.1–727.3 1667.5 401.3–4647.1 2068.6 684.1–5136.5
95% UI¼95% uncertainty interval (2.5–97.5th percentile)
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Fig. 3. Sensitivity analysis of to evaluate the effect of changing prevalence of NCC (0.5 , 1 , 1.5 and 2 (times) of the input
values) on disability adjusted life years (DALY) due to neurocysticercosis (NCC)-associated active epilepsy.
B.B. Singh et al. / Data in Brief 7 (2016) 571–5815761. Data
Demographic and epidemiologic data along with the associated R code used for estimating the
health and economic impact are presented in R-code. The data indicating the effect of changing
prevalence and per capita income on economic losses for NCC are presented in Figs. 1 and 2. The
values of sensitivity analyses to evaluate the effect of changing prevalence, per capita income, pro-
portion of people seeking medical attention and case fatality on DALY for NCC in India are presented
in Table 1 and the associated results in Figs. 3–7. Results for three scenarios with different age
weighting (k) and time discounting (r) are presented in Table 1 and the results for the scenario
without any age weighting and time discounting are presented in “Estimation of the health and
economic burden of neurocysticercosis in India” [1].
Fig. 4. Sensitivity analysis to evaluate the effect of changing the proportion of human neurocysticercosis (NCC) cases seeking
allopathic medical attention (from 0.2 to 1) on disability adjusted life years (DALY) due to NCC-associated active epilepsy.
B.B. Singh et al. / Data in Brief 7 (2016) 571–581 5772. Experimental design, materials and methods
The demographic and epidemiologic data were collected by review of the national and
international peer reviewed literature as well as sourced from government agencies [1]. The
health and economic impact of neurocysticercosis was estimated as per published scientiﬁc
literature [2–4]. The analyses were conducted (Fig. 1) in R-statistical programme (R statistical
Fig. 5. Sensitivity analysis to evaluate the effect of changing the proportion of human neurocysticercosis (NCC) cases seeking
allopathic medical attention (from 0.2 to 1) on years of life lived with disability (YLD) due to human NCC-associated active
epilepsy.
B.B. Singh et al. / Data in Brief 7 (2016) 571–581578package version 3.2.2, R Development Core Team (2015), http://www.r-project.org). To compute
95% uncertainty interval (UI) (deﬁned as 2.5–97.5th percentile), the authors ran Monte Carlo
simulations for 10,000 iterations. The R code along with associated data [5-12] has been pro-
vided as supplementary material (Appendix A).
Fig. 6. Sensitivity analysis of to evaluate the effect of changing case fatality of NCC (0.5 , 1 , 1.5 and 2 (times) of the input
values) on disability adjusted life years (DALY) due to NCC-associated active epilepsy.
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Fig. 7. Sensitivity analysis to evaluate the effect of changing case fatality of neurocysticercosis (NCC) (0.5 , 1 , 1.5 and 2
(times) of the input values) on years of life lost (YLL) due to NCC-associated active epilepsy.
B.B. Singh et al. / Data in Brief 7 (2016) 571–581580Appendix A. Supplementary material
Supplementary data associated with this article can be found in the online version at http://dx.doi.
org/10.1016/j.dib.2016.02.079.References
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